Goldman Sachs analyst Madhu Kumar upgraded Krystal Biotech to Buy from Neutral with a price target of $124, up from $79. The May 19 FDA action date for collagen 7 herpes simplex virus gene therapy drug Vyjuvek for dystrophic pidermolysis bullosa remains the key near-term event for shareholders, the analyst tells investors in a research note. The firm’s 90% probability of success and investor conversations indicate potential approval and debates around Vyjuvek are now primarily focused on the launch, says the analyst. The firm believes approval could drive further upside in Krystal shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech reports Q4 EPS ($1.25), consensus ($1.32)
- Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
- Krystal Biotech CEO sells $4.04M in common stock
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
- EC grants Krystal Biotech orphan designation for KB407 for CF treatment
